Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Naltrexone well tolerated and effective in pruritus caused by cholestasis

Jan. 28, 2003

Two courses of alefacept evaluated in patients with chronic plaque psoriasis

Jan. 24, 2003

QRX-101 phase II trial in psoriasis cleared to begin

Jan. 24, 2003

Efficacy of TAK-427 in experimental model of atopic dermatitis

Jan. 23, 2003

Positive phase III results for Enbrel in psoriasis

Jan. 21, 2003

Tacrolimus reported safe and effective in chronic actinic dermatitis

Jan. 20, 2003

Shire licenses Solaraze rights in Australia and certain Pacific Rim territories

Jan. 17, 2003

Access licenses amlexanox to Zambon

Jan. 16, 2003

Velac enters phase III development program for acne

Jan. 9, 2003

Proof of concept established in patients for Arachnova's product for dermatitis

Jan. 9, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...